IJBPAS, June, 2023, 12(6): 2440-2466

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

ANTI-PSORIATIC ACTIVITY OF VARIOUS HERBAL PLANTS - A COMPREHENSIVE REVIEW

KETHIREDDI SL[*1], SRI RC[2], THALLA S[3] AND NADENDLA RR[4]

Department of Pharmacology, Chalapathi Institute of Pharmaceutical Sciences (Autonomous)

Guntur-522034, Andhra Pradesh, India

[*]**Corresponding Author: Sai Lakshmi Kethireddi: E Mail: sailakshmikethireddi81@gmail.com**

Received 10th June 2022; Revised 15th July 2022; Accepted 3rd Aug. 2022; Available online 1st June 2023

https://doi.org/10.31032/IJBPAS/2023/12.6.6927

ABSTRACT

Psoriasis is a chronic inflammatory skin disease that has a wide range of clinical appearances and is triggered by a number of genetic, environmental, and immunological factors. Psoriasis has been the domain of quarter century of clinical and basic research, which has revealed many of the disease's pathogenic mechanisms and led the floodgates for effective and affordable therapy. Here, we look back on our progress and highlight literature reviews related to synergism of herbal drugs and various treatments that are endorsed by a more interpretative research paradigm and seek to broad range of users even more.

Keywords: Psoriasis model, eczema, dermatitis, psoriasis area and severity index, imiquimod-induced, anti-psoriatic agents

INTRODUCTION:

Psoriasis is a group of severe skin conditions that have a detrimental affect on a patient's quality of life. It concerns 2% of the general population under 35 years old and occurs in the preponderance of populations with a high incidence of 1-3 percent. Many accessible and affordable psoriatic medications are currently unavailable for treatment. There are a variety of treatments available, apart from antibody therapy, synthetic immunizations, herbal extracts and formulations, and so on. But, even though nanostructured drugs are

more potent in psoriasis but have severe unprecedented deterministic effects that appear with protracted drug use, more than 50% of psoriatic patients around the world are using complementary interventions with different formulae, topically, internally, and in combination therapy. Recent studies emphasizing on synergism have tried to integrate different drugs constitutes a better psoriasis cure. When pales in comparison to all other medications, patients who were prescribed combinations in various forms showed targeted clinical index with minimal scarring.

LITERATURE:

Liu Liu *et al*., (2022) investigated Celastrol gel ameliorates imiquimod-induced psoriasis-like dermatitis in mice by targeting Langerhans cells using female C57BL/6 and Langerin-diphtheria toxin receptor (DTR) mice were split into two groups: Vehicle and Cel gel. In order to create the mouse model of psoriasis, IMQ was utilised to promote psoriatic inflammation. Changes in local inflammatory cells in the skin lesions were explored employing hematoxylin and eosin staining. Flow cytometry was analysed to evaluate cell number and cytokine expression, whereas ELISA was employed to assess protein expression levels. PCR was used to descry cytokine gene expression. In IMQ-induced psoriatic dermatitis, the gel hindered the interaction allying Langerhans cells and T cells by diminishing interleukin (IL) 23 release by Langerhans cells.As a response, the proportion of activated T cells as well as related IL-17 outflow were reduced, easing psoriatic inflammation, and the gel also demonstrated a glucocorticoid-like response that could avoid psoriasis from recurrence **[1]**. María Morell *et al*., (2022) explained that SIDT1 plays a key role in type 1 IFN responses to nucleic acids in plasmacytoid dendritic cells and mediates the pathogenesis of an imiquimod-induced psoriasis model by an unclear mechanism andSIDT1's function in natural IFN-producing cells, plasmacytoid dendritic cells, was also investigated (pDC). Silencing SIDT1 expression in the GEN2.2 cell line and human primary pDC culminated in an attenuation of the IFN-I response after stimulation of TLR7 and TLR9, with no benefit on pro-inflammatory responses or maturation marker amplification. After CpG stimulation, SIDT1 migrates from the ER to the endosomal and lysosomal compartments with TLR9, aiding and abetting the TLR9-CpG complex in connecting lysosome-related vesicles, as per study. As a direct consequence, sidt1/ mice reported a decrease in severity parameters of the imiquimod-

induced acute psoriasis-like model, which was associated with a decrease in the extent of IFN-I and IFN-dependent chemokines. SIDT1 is at the convergence of the IFN-I and proinflammatory pathways, implying that it might be an adequate therapeutic target for psoriasis and other maladies mediated by IFN-I responses **[2]**.

Philip E. Stuart *et al*., (2022) performed a Transethnic analysis of psoriasis susceptibility in South Asians and Europeans enhances fine mapping in the MHC and genome-wide (GWAS) 2,590 patients and 1,720 controls were included in this study.. The effect sizes of known psoriasis signals in SAS and EUR were strongly associated, and the Transethnic meta-analysis discovered two distinct histocompatibility complex (non-MHC) psoriasis genes not previously disclosed in EUR, which might also play regulatory roles. The transethnic GWAS revealed improved genetic resolution and reduced down the number of putative causative variants for these two loci compared to utilising the EUR sample alone. They then tried a variety of concepts and developed authorized panels for reliably appending MHC genotypes in EUR and SAS populations and performed a fine navigation of MHC psoriasis associations in SAS, which was the largest effort that ever was. HLA-C*06 was the top-ranking MHC locus in both clusters based on odds ratio, ailment liability, model fit, and prediction accuracy, but it was considerably more conspicuous in SAS. Transethnic modelling considerably enhanced the likelihood that the HLA-C*06 protein mutation is pertinent. Secondary MHC signals encompassed HLA-C and HLA-B coding anomalies, as well as HLA-A and certain HLA class II genes with effects on chromatin integrity and epigenetics. The shared genetic foundation of psoriasis in EUR and SAS populations was underlined in this work, as was the value of transethnic meta-analysis in the finding and fine mapping of susceptibility loci **[3]**. Renu Mahtani *et al*., (2022) suggested the Daily oral vitamin D_3 without concomitant therapy in the management of psoriasis: A case series, with 6 cases of psoriasis being treated with daily oral Vitamin D_3 (25 hydroxy cholecalciferol) at dosages ranging from 30,000 IU to 60,000 IU for 2 to 6 months, preceded by a lower daily maintenance dose. The Psoriasis Area and Severity Index (PASI) and a symptom Visual analogue scale had been used to determine complete control of psoriasis during a timeframe of 2–6 months. According to the findings, the daily oral vitamin D_3 monitored was higher than usual and so can be provided safely as an

effective therapeutic tool for psoriasis treatment **[4]**.

King-Jean Wu *et al*., (2021) assessed that Severity of periodontitis and salivary interleukin-1b are associated with psoriasis involvement. The immune response to the microbiota living on epithelial surfaces is defined by psoriasis and periodontal illnesses, so the investigators tried to explore the links between psoriasis severity and periodontal pathology in psoriatic subjects.Thirty-three subjects with psoriasis were enrolled from National Taiwan University Hospital's dermatology clinic for the study. The patients who filled the informed consent forms had a full-mouth periodontal examination and saliva was sampled from them. The Luminex Bio-Plex system had been used to test salivary cytokines such like interleukin (IL)-1b, IL-12, IL-17, tumour necrosis factor (TNF)-a, and interferon-g, as well as clinical periodontal parameters such as probing depth (PD), gingival index (GI), plaque index (PI), and clinical attachment level (CAL).Underlying comorbidities such as anti-inflammatory medication, tobacco use, were also included in the analysis **[5]**.

FundaKemeriz *et al*., (2021) studied on the Evaluation of ocular psoriasis with meibography. Uveitis, conjunctivitis, blepharitis, and dry eye are associated with psoriasis. Yet, ocular manifestations of psoriasis may be adroit and present sub-clinically the meibomian glands (MG) or sebaceous glands situated in the eyelids that exude lipids and keep tears from dissipating and play a vital role on the ocular surface. Meibomian gland dysfunction is a chronic condition typified by terminal duct obstruction and/or modifications in secretions' quantitative and qualitative attributes. MGD affects anything from 3.5 percent to 74.5 percent of people. MGD has been detected using MG plugging, Meibomian secretions, telangiectasia, gland loss, and a combination of these factors. A significant relationship has been found between psoriasis and MGD in studies, but meibography has not been used in the studies with psoriasis although this non-invasive approach has now been widely preferred for clinical use and allowed undertaking of many clinical studies about meibomian gland diseases and in addition, meibography allows objective observation of meibomian glands **[6]**.

JooEun Shin *et al*., (2021) deliberated that IOX1 impedes host inflammation in imiquimod-triggered psoriasis. The therapeutic potential of 8-hydroxyquinoline-5-carboxylic acid (IOX1), a putative

therapeutic with a genetic target, in the treatment of psoriasis was addressed. In a mouse model of imiquimod (IMQ)-induced psoriatic inflammation, day-to-day topical application of IOX1 reduced inflammatory reactions in the skin and reduced the PASI score, and intraperitoneally injected IOX1 suppressed the inflammatory status induced by IMQ in psoriatic mice by reducing pro-inflammatory cytokine mRNA levels, restoring splenocyte populations, and regulating macrophage polarisation **[7]**. Kamlesh Wadher *et al*., (2021) described the Evaluation of anti-psoriatic activity of gel containing *Pongamia pinnata* extract on Imiquimod-induced psoriasis. A hydroalcoholic leaves extract of *Pongamia pinnata* had been used for phytochemical screening and quantitation of phytoconstituents. The herbal gel was synthesized with Carbopol 934 as the gelling agent, and the gel formulations were assessed for pH, viscosity, spreadability, and in vitro diffusion. The extract's anti-psoriatic effect was apparent through index grading in the imiquimod-induced model of psoriatic mice. The extract therapy confirmed a convincing decrease in the treated groups with psoriasis, with substantial reductions in skin thickness and scaling **[8]**.

Tingting Di *et al*., (2021) studied and revealed that *Tuhuaiyin* alleviates imiquimod-induced psoriasis via inhibiting the properties of IL-17-producing cells and remodels the gut microbiota. Epidermis proliferation is triggered by an accumulation of IL-17 cytokines in the lesions. Traditional Chinese herbal medicine has a substantial effect on the progression of psoriasis, and *Tuhuaiyin* is a notable prescription that has a remarkable curative effect in both the acute and convalescent stages. *Tuhuaiyin* network interaction with substances, targets, and disorders was constructed using a database screening and systematic pharmacology platform to uncover the target and reminiscence of *Tuhuaiyin*. *Tuhuaiyin's* effect on keratinocyte proliferation and inflammation was validated in a model of psoriasis-like lesions provoked by imiquimod, as was its effect on the frequency and function of IL-17-producing cells, as well as *Tuhuaiyin's* regulatory effect on gut microbiota *Tuhuaiyin's* 32 active molecules acted on psoriasis biological processes, diminishing erythema and scales in a psoriasis-like mouse model caused by imiquimod, as well as excessive keratinocyte proliferation and inflammatory cell intrusion in the dermis. In the skin and peripheral blood, the utterance of IL-17 was suppressed.

In the psoriasis-like model, the number of Interleukin-17producing cells was reduced in immunological organs, JNK phosphorylation was suppressed in skin lesions, and gut microbial diversity was improved **[9]**. Jared Liu, *et al*., (2021) described a study on Transcriptomic profiling of plaque psoriasis and cutaneous T cell subsets during treatment with secukinumab. To better understand its mechanism of action, investigated its impact on psoriatic lesions from 15 moderate-to-severe plaque psoriasis patients who received secukinumab treatment were monitored for 12 weeks to see how transcriptomic variations in intact lesional skin tissue, cutaneous CD4+ T regulatory cells and CD4+ and CD8+ T effector cells shifted over time. Secukinumab was clinically efficacious, diminishing disease-associated amplification of IL17A, IL17F, IL23R, IL23A, and IFNG in whole tissue as long as 14 days after intervention began. Over expression of IL17A was also reduced in T cell subsets, predominantly CD8+ T cells. While the treatment with secukinumab resolved 89-97 percent of psoriasis-related expression difference in proportions tissue and T cell subsets by week 12, the changes were accompanied by shifts in broader immune cell composition based on deconvolution of RNA-seq data, and the study also revealed several phenotypic and cellular changes within the lesion that underpin clinical improvement from secukinumab **[10]**.

Yibo Hu, *et al*., (2021) studied on the Establishment and validation of psoriasis evaluation models. The assessment is based on the psoriasis area and severity index, and the diagnosis has been mostly based on clinical and pathological aspects (PASI). This investigation used GEO datasets to uncover 17 model genes and used LASSO regression, linear regression, and random forest to create 6 psoriasis evaluation models. Across several GEO datasets, models were instructed and assessed. In training and testing data, all six models correctly discriminated psoriatic lesions and non-lesional skin, with good AUC. The model scores were favourably connected with the severity of lesions in biologics-treated samples and negatively correlated with treatment length. As a result, models can be used to measure therapy outcomes **[11]**. Fen Qiu, *et al*., (2021) evaluated Celastrol Niosome Hydrogel has anti-Inflammatory effect on skin keratinocytes and circulation without systemic drug exposure in psoriasis mice. The uptake of Nio by HaCaT cells was assessed using flow cytometry, and the anti-inflammatory effect was detected using

qPCR in the in vitro investigation. Immunofluorescence was used to quantify the expression of inflammatory factors and Ki-67 in the skin. Cel was mostly heaped up in the skin when mice were given Cel Nio gel topically. Furthermore, Nio preparation increased HaCaT cell uptake, while Cel significantly reduced inflammatory cytokine mRNA levels and expression in HaCaT cells, as well as Ki-67 expression in skin **[12]**.

AkachukwuIbezim *et al*., (2021) performed study based on A computational multi-targeting approach for drug repositioning for psoriasis treatment. This made attempts to relocate approved drugs for the psoriatic treatment by docking, about 2000 approved drug molecules against fifteen picked and corroborated anti-psoriatic targets. The docking findings confirmed that a sizeable proportion of the dataset combined well with the targets, with most of them having - 11.00 to - 10.00 kcal/mol binding free energies across the targets, and the percentage of the dataset with binding capacity higher than the co-crystallized ligands scaled from 34.76 percent (JAK-3) to 0.73 percent (Rac-1), with 12 out of 0.73 percent outperforming all co-crystallized ligands across the 12 medicines developed have purine and pyrimidine nuclei and are indicated as antiviral or anticancer medications **[13]**.

Nikolai Loft *et al*., (2021) performed Disease burden, symptoms, and use of analgesics in patients with psoriasis with or without psoriatic arthritis: A cross-sectional study. The general population from the Danish Skin Cohort, which included 4016 psoriatic patients and 3490 controls, was analysed to estimate the common attributes in psoriatic patients with and without PsA, general health and use of analgesics. Itching, skin pain, and/or joint pain were linked to a worsening in general health in PsA patients. Only joint pain was linked to opioid use (odds ratio, 3.72 (2.69-5.14); P.0001) **[14]**.

Q. Beytout *et al*., (2021) performed a survey on Impact of the COVID-19 pandemic on children with psoriasis. The method involves a survey of children (< 18 years) with psoriasis, performed from June 10 to June 29, 2020 and the results include a total92 children of which 71.7% during times of domestic isolation i.e., lockdown, 45.2 percent had psoriatic lesions, 45.2 percent were taking systemic therapies, and two had COVID-19. Psoriasis worsened in 47.3 proportion of the adolescents during the lockdown, and 18.8 percent stopped taking their systemic treatments, owing to the pandemic. During lockdown, 41.3 percent of patients had a psoriasis consultation (71.1 percent via tele-consultation): 39.5 percent

for worsening psoriasis and 21.1 percent for pandemic-related issues; among those who don't have an advice during quarantine, 27.5 percent dropped due to doctor concerns and 9.3 percent had concerns about going to see the doctor. Finally, 22.8 percent of patients said it was difficult for them to follow hygiene rules because of their teleconsultations. Teleconsultations were important in patient management since they allowed for patient monitoring, information sharing, and treatment renewal. In the event of a future health crisis, it is imperative to learn from this evidence in order to better and adapt surveillance of chronic eczema in children and adults **[15]**. Gleison Vieira Duarte, MD *et al*., (2021) explained Generalized pustular psoriasis in Brazil: A public claims database study. They aimed to give a brief account on epidemiology and therapy of GPP in Brazil from public health care system perspective based on information in records of health resource utilisation by patients with GPP, and stated that a total, 1458 outpatients of all ages were recognised, with 53 percent of them to be women, and evaluated the GPP prevalence in Brazil to be in between 0.7 and 0.9 per 100,000.The most usually prescribed drug was acitretin. In the inpatient database, 769 outpatients were found, and 151 of them had hospital admissions throughout the study period. During their stay in the hospital, 5.3 percent of them died. The most probable explanation for admittance was a basic skin disease or infection **[16]**.

Achilleas Diakomopoulos *et al*., (2021) performed a study for better Understanding the enigmatic association between mycosis fungoides and Psoriasis. The research's main goal is to examine the link in between MF and psoriasis by presenting two instances with diagnostic and cytologic characteristics. Medical practice should include biopsy of cutaneous lesions prior to the administration of biologics. When psoriasis form lesions popped up, a biopsy of cutaneous lesion was also performed. Finally, to gather data and clarify the enigmatic relationship between psoriasis, MF, and immunosuppressive treatment, a large multicentric registry of the MF patients who were treated for eczema, psoriasis with classic immunosuppressive drugs and/or biologics was compelled **[17]**. Danielle Perna, BS *et al*., (2021) studied on the Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. They had given a brief description on the first reported case of AGPP following the COVID-19 messenger RNA (mRNA) vaccine. Dermatologists have traditionally avoided using systemic steroids in psoriasis

patients for concern of causing AGPP during discontinuation. An acute, rapidly increasing skin eruption manifested in man during his 40s with morbid obesity, hypertension, depression/anxiety, and psoriasis. His pre-existing psoriasis had been persistent for years, with emollient-treated transitory plaques that were only mildly bothersome. Lisinopril and bupropion, which he had taken a month prior, were among his prescriptions. He received the Pfizer vaccine (first dose) 5 days just before rash emerged, and he had no recent illnesses or medication exposures. Biopsies divulged psoriasis form dermatitis with intraepidermal neutrophilic pustules, supporting the clinical diagnosis of AGPP, and thus significant improvement after 3 days of treatment was observed, and he was discharged with pustular psoriasis wiped clean and started on secukinumab as an outpatient, concluding that there is a progression experienced by patients when medication is disrupted. Researchers discovered that proteins produced in response to the vaccine trigger the production of interleukin 6, which promotes the development of Th1 and Th17 cells, which in turn trigger the discharge of downstream cytokines that play a pivotal role in the development of AGPP epidermal changes **[18]**.

Lakshmi. JN, *et al*., (2020) performed a research on Evaluation of anti-psoriatic activity of selected phytochemicals on UV-induced psoriasis in mouse tail model. The animals were divided into 05 groups (5/group). The disease control group is only exposed to UV light, the vehicle control is nursed with simple ointment, the standard was nursed with salicylic acid (1 percent w/w) ointment, and the other groups are treated with 1 percent and 2 percent selective phytochemicals of varying concentrations applied to the animal's tail. The data was analysed using one way followed by two-way ANOVA showed the significant decrease in epidermal thickness when compared with the control the study finally revealed that the phytochemicals of different concentrations exhibited significant activity on UV-psoriasis in rodents **[19]**. Hsin-Ju Li *et al*., (2020) studied that Chrysin alleviates imiquimod- induced psoriasis-like skin infammation and reduces the release of CCL20 and antimicrobial peptides. The data confirmed that chrysin substantially lowered imiquimod-induced psoriatic lesions in mice and improved imiquimod-induced skin barrier disruption. Moreover, pre-treatment with chrysin of epidermal keratinocytes drastically decreased TNF-, IL-17A, and IL-22-persuaded phosphorylation of MAPK and

JAK-STAT pathways, as well as activation of the NF-B pathway. Most importantly, chrysin hampered TNF, IL-17A, and IL-22-instigated CCL20 and antimicrobial peptide release from epidermal keratinocytes, implying that chrysin may have therapeutic potential against inflammatory skin diseases. The findings also provide a foundation for further research into chrysin as a novel pharmacologic agent, as well as an advancement in the field of Chinese herbal medicine **[20]**.

Shoufan Wang *et al*., (2020) examined Salvianolic acid B ameliorates psoriatic changes in imiquimod- induced psoriasis on BALB/c mice by inhibiting inflammatory and keratin markers via altering phosphatidylinositol-3-kinase/protein kinase B signalling pathway. A total of 50 healthy BALB/c mice were randomly assigned to one of five groups: control, drug control (SAB; 40 mg/kg), IMQ-induced psoriasis (5%), IMQ exposed plus treatment with SAB (40 mg/kg), or conventional methotrexate (MTX; 1 mg/kg). Psoriasis area severity index, erythema, scaling, skin thickness, inflammatory indicators (interleukin [IL]-22/23/17A/1/6) and lipid peroxidation product were all considerably reduced in mice given either SAB or MTX (malondialdehyde). The protein expression of keratin markers (K16 and K17) and phosphatidylinositol-3-kinase/protein kinase B (Akt) signalling proteins (pAkt/Akt and pPI3K/PI3K) modulating proteins (pAkt/Akt and pPI3K/PI3K). Signalling protein (pAkt/Akt and pPI3K/PI3K) was significantly downregulated after administration. By diminishing psoriatic inflammatory and keratin indices and restricting the PI3K/Akt biochemical pathway, the combination of SAB and MTX effectively improved psoriatic alterations. Further researches (clinical trials) are required to demonstrate the anti-psoriatic potential of SAB before suggesting to psoriatic patients **[21]**. Mostafa Khaledi *et al*., (2020) performed a study on Chemical profiling and anti-psoriatic activity of Marine sponge *(Dysideaavara)* in induced imiquimod-psoriasis-skin model. In in-vivo testing, psoriatic mice were fed with three varied methanolic extracts of *Dysideaavara* and compared to Betamethasone-treated animals. The severity was quantified using the psoriasis area index, while TNF-, IL-17A, and IL-22 expression was measured using an ELISA. To examine single compound potential anti-inflammatory activity, the extract activity was assayed using GC-MS, HPTLC, and SEA DOCK.After one week of treatment, the mice treated with extract

revealed a dose-dependent, notable improvement compared to controls ($p< 0.001$). Following treatment, ELISA displayed a statistical drop in IL-22, IL-17A, and TNF-, and the SEA DOCK analysis put forward that the extracts may have anti-psoriatic effect **[22]**.

Asogwa F.C. *et al*., (2020) studied the Anti-psoriatic and immunomodulatory evaluationof *Psorospermum febrifugum Spach* and its phytochemicals. *Psorospermum febrifugum Spach* is a flowering plant belonging to the family Hyperpericacea. It's been used in folk medicine for a long time as a therapy for leprosy, epilepsy, insomnia, anxiety, subcutaneous wounds, and skin irritations. The 2,4-dinitrofluorobenzene induced psoriasis model was used to investigate aqueous and ethanolic extracts from the leaf and stem bark for their activity. According to the studied parametersethanolic stem bark extract showed better anti-psoriatic activity (93.15%) irrespective of solvent system. The active extract was detached into fractions that reduced epidermal thickness in the rats by 18.25–71.12 percent and 35.77–93.11 percent, respectively, at 200 and 400 mg/kg body weight doses. *P. febrifugum* was revealed to have outstanding anti-psoriatic and immunomodulatory properties in the study **[23]**. Sumate Ampawong *et al*., (2020) studied for Evaluating the effect of rice *(Oryza sativa L*: SRNC05053-6-2) crude extract on psoriasis using in vivo and in vitro epidermis models. Rice crude extract consists of anthocyanin, which exhibits strong antioxidative and anti-inflammatory properties. This was evaluated using human psoriatic artifcial skin and an imiquimod-induced rat psoriasis model. Psoriasis-related genes, cytokines, and chemokines were addressed, as well as the condition's antioxidative, anti-inflammatory, and immunohistopathological aspects. The results showed decrease in the severity of psoriasis by (1) reducing the epidermal thickness, hyperkeratosis, acanthosis, epidermal infammation and degree of apoptosis induction via caspase-3, (2) increasing the expression range of anti-infammatory cytokines (IL-10 and TGF-β), (3) reducing the levels of pro-infammatory cytokines (IL-6, IL-8, IL-20, IL-22 and TNF-α), chemokines (CCL-20) and anti-microbial peptides (psoriasin and β-defensin), (4) enhancing the antioxidative property (Nrf-2), (5) downregulating the levels of psoriasis-associated genes (psoriasin, β-defensin, koebnerisin 15L and koebnerisin 15S) and (6) upregulating the levels of psoriasis-improving genes (caspase-14, involucrin and

flaggrin) and concluded that the extract appears to exert therapeutic effects on psoriasis through its antioxidative and immunomodulatory properties **[24]**.

Sobia Ahsan Halim *et al*., (2020) experimented on Diterpenoids and Triterpenoids from frankincense are excellent anti-psoriatic agents: An *in silico* approach. Bioinformatics approach was used to evaluate the potency of individual active components. Following the identification of relevant druggable psoriasis targets, structure-based screening was used to target compounds against 18 plausible psoriasis targets using three distinct docking techniques and score mechanisms. Janus Kinase 1, 2, 3, eNOS, iNOS, interleukin-17 (IL-17), and tumour necrosis factor (TNF-) genes have all been found. This research shows that frankincense di and triterpenoids can be effective anti-psoriatic drugs by targeting key cytokines (IL-17, TNF-, IL-13, IL-23, and IL-36,) which are aggravated in psoriasis, as well as inflammatory pathways such as eNOS, JAK1/2/3, iNOS, MAPK2, and IFN **[25]**. Divya Bharathi *et al*., (2020) evaluated the Assessment of anti-psoriatic activity of ethanolic extract of *Justicia tranquebariensis Linn*. on amelioration of IMQ-induced hyperkeratosis in Balb/C mice. The ethanol extract of *J. tranquebariensis L.* leaves demonstrated the presence of major phytochemicals such as flavonoids and lignans (EJTL). Furthermore, the existence of the requisite functional groups were corroborated by UV-Visible and FTIR, confirms the presence of Isolariciresinol. In mice with imiquimod (IMQ) generated psoriasis-like inflammation, in vivo testing of the EJTL ointment exhibited substantial anti-psoriatic potential. The anti-psoriatic activity was further confirmed by diminished lymphocyte and keratinocyte infiltration in the dermis, and a brief phytochemical characterization highlighted the presence of the active botanical ingredient, Isolariciresinol, which was assumed to have anti-psoriatic properties, and the EJTL could also be a potential psoriasis drug **[26]**.

Anitha, R *et al*., (2020) studied the Anti-Psoriatic activity of *Indigofera tinctoria* leaves extract on *Staphylococcus aureus* embedded HaCat cells: A Systematic approach. *Indigofera tinctoria* from the Kolli hills of Tamil Nadu was phytochemically screened against a bacterial bacterium that causes psoriasis, and a crude extract was prepared using a solid-liquid extraction step, which was then tested for in-vitro antibacterial activity against *Staphylococcus aureus* using the agar well diffusion method at a concentration of 50 mg/ml. When

compared to the common antibiotic Tetracycline, the extract exhibited improved activity (31–33 mm of zone of inhibition).Furthermore, the percentage activity of *Indigofera Tinctoria* extract showed maximum inhibition of about 58.95 percent at 150 g/ml in the Sulphorhodamine B (SRB) assay on *Staphylococcus aureus* embedded HaCat cell lines, and the pieces of evidence showed potential anti activity in Hacat cell lines with IC50 value of 68.7514.80 g/ml in cytotoxicity method, which is comparable to standard drug **[27]**.

Janani Jacob *et al*., (2019) performed a study on Evaluation of anti-psoriatic potential of the fruit rind of *Punica granatum L*. As the previous study isolated the compounds and evaluated for antioxidant potential, and so the study was taken up to evaluate the extract and compounds for anti-psoriatic activity (in-vitro) by the chromatographic techniques which were put forth to isolate the compounds from the acetone extract (aqueous) and the inhibition assay of thymidine phosphorylase was done to determine the in vitro anti-psoriatic activity. The phytochemical investigation identified three compounds known to be as Punicalagin, 2,3(S)-hexahydroxydiphenoyl-D-glucose and Punicalin were examined for the psoriatic activity. The results exhibited that the isolated three compounds showed inhibitory activity of 89% to 95% against thymidine phosphorylase and the aqueous acetone extract exhibited 87% inhibition. Finally the study concluded that *Punica granatum* is an ideal plant for further investigation to prove its anti-psoriatic activity **[28]**.

Negi.P., *et al*., (2019) studied the Thymoquinone-loaded lipid vesicles: a promisingnanomedicine for Psoriasis. Thymoquinone (TQ) is a lipid-soluble benzoquinone that is a prominent active element in *Nigella sativa* (NS) volatile oil and has anti-psoriatic properties. Its development is hampered by its hydrophobicity, low aqueous solubility, and photosensitivity. The research assessed the ethosomal vesicles (EVs)loaded with TQ prepared by cold method and characterised for various essential attributes to evaluate its anti-psoriatic potential employing mouse-tail model resulting in % anti-psoriatic drug activity to be substantially better in case of TQ loaded ethosomal gel, NSextract and marketed formulation by good permeation of *Nigella sativa* **[29]**.

Ayesha Husna S *et al*., (2019) performed the Evaluation of antipsoriatic activity of aqueous extract of *Brassica Oleracea var*. The impact of capitata and ethanolic extracts

of *Mentha spicata* leaves on imiquimod-induced psoriasis-like dermatitis in Swiss albino mice were studied at doses of 100 mg/kg b.wt. and 400 mg/kg b.wt. changes in the weight of body, weight of spleen and spleen index, lymphocytes, neutrophils, eosinophils, monocytes, haemoglobin, RBC's, platelets, packed cell volume, mean corpuscular volume, mean corpuscular haemoglobin (MCH), MCH concentration, erythema, epidermal thickness, skin thickness, desquamation, superoxide dismutase. Finally, as compared to MSEE at low doses, MSEE at 400 mg/kg b.wt displayed stronger influence and BOAE topical and oral concluded to have antipsoriatic activity **[30]**.

Anitha Ravi *et al*., (2018) studied the Antioxidant activity and in silico analysis of *Centella asiatica and Indigofera aspalathoides* in psoriasis with (VEGF) vascular endothelial growth factor and inflammatory marker IL-17 in silico analysis, which is an important factor for targetting the psoriasis. The active compounds of the whole plant were extracted using ethanol, ethyl acetate and were screened for the presence of antioxidants by antioxidant scavenging activity- hydroxyl radical, superoxide anion radical, and nitric oxide radical and (1,1-Diphenyl-2-picrylhydrazyl) DPPH assay. Patch dock server was used to analyse chemical interactions with (VEGF) Vascular endothelial growth factor (VEGF) and interleukin-17 (IL-17) utilising an in silico technique. The cell toxicity was tested using the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in L929 fibroblasts. When compared to the control using the in silico method, The ethanolic extract of *Indigofera aspalathoides* extract (FSE) had better antioxidant scavenging activity, and compounds like dodecanoic acid,10 methyl-,methyl ester, and Pregnan-18-oic acid, 20-hydroxy-,[5alpha] had better ability and produced docking scores of 26.47 and -30.56 with VEGF and interleukin-17, respectively **[31]**. Takeshi Kawahara *et al*., (2017) Effect of the topical application of an ethanol extract of *Quince* seeds on the development of atopic dermatitis-like symptoms in NC/Nga mice. The direct impact of QSEtE on keratinocytes was explored using the human keratinocyte cell line HaCaT. In HaCaT cells, QSEtE downregulated and directly thwarted the expression and synthesis of thymus and activation-regulated chemokine (TARC), and it reduced house dust mite allergen-induced skin lesions. The research suggests that topical application by diminishing TARC synthesis in keratinocytes, quince seed

ethanolic extract is efficient in slowing down the process of atopic symptoms of keratinocyte-associated skin inflammation and ameliorating atopic symptoms of keratinocyte-associated skin inflammation **[32]**.

Han-Qing Liu *et al*., (2017) evaluated the Anti-Psoriasis effects and mechanisms of A-(8-Quinolinoxy) Zinc Phthalocyanine-Mediated photodynamic therapy by using HaCaT cells to observe ZnPc-F7-PDT influence on cell proliferation in vivo and the in vitro anti-psoriatic effect of ZnPc-F7-PDT were evaluated using, a propranolol-induced cavy psoriasis model, a mouse vagina model and an imiquimod (IMQ)-induced nude mouse psoriasis model. T lymphocyte levels were determined using flow cytometry, protein expression was determined using Western blotting, and mRNA expression was determined using a reverse transcription polymerase chain reaction assay. ZnPc-F7-PDT significantly suppressed HaCaT cells proliferation in vitro, according to the findings; light dosages were fixed, and changing the irradiation period or the function returns had minimal effect on the inhibition rate. ZnPc-F7-PDT decreased diethylstilbestrol-induced hyperproliferation of the mouse vaginal epithelium and alleviated propranolol, psoriasis-like symptoms induced by IMQ, as well as IMQ-induced splenomegaly and T lymphocyte abnormalities in the mouse vaginal model, ZnPc-F7-PDT did not appear to affect T cells. ZnPc-F7-PDT inhibited the expression of proliferating cell nuclear antigen (PCNA), B-cell lymphoma-2 (Bcl-2), interleukin (IL)-17A mRNA, and IL-17F mRNA, while increasing the expression of Bax. The researchers concluded that ZnPc-F7-PDT has therapeutic effects in psoriasis both in vivo and in vitro, and could be a potential **[33]**.

Thomson Alex *et al*., (2017) examined for the Evaluation of anti psoriatic activity of *Karanjin* oil. Inflammatory mediators such as cytokines were used as biomarkers in the Imiquimod psoriasis model, and qRT-PCR was performed to evaluate cytokines concentration in the blood serum of psoriasis generated mice. The pathophysiology of psoriasis and the levels of cytokines were checked in both control and standard and finally the drug *Karanjin* oil was manifested to have anti-psoriatic activity **[34]**.

Rajkiran Reddy Banala *et al*., (2017) evaluated Aqueous extract of *Acalypha indica* leaves for the treatment of psoriasis: In-vitro studies using A431 and B16-F10 cell lines as in vitro models. The study aimed at analysing the feasibility of *Acalypha indica* leaf extract in inducing apoptosis and cell

death in cell lines and assessing the anti-psoriatic activity of aqueous extract of *Acalypha indica* Cell death (Propidium iodide) and apoptosis (Annexin V) were assessed using fluorescence studies, and 80 percent of cell death and 75 percent of apoptosis were found in both cell lines, indicating that the in vitro research of the leaf extract is capable of serving as an anti-psoriasis agent **[35]**. Komal M. Parmar, *et al*., (2016) studied the Anti-psoriatic potential of *Solanum Xanthocarpum* stem in imiquimod-induced psoriatic mice model. The stem and fruits were used as an antipyretic, anti-asthmatic and was advised in skin infections and for the relief in burning sensation in the feet accompanied by vesicular eruptions. The treatment was carried out for 15 days both topically (Gel at 2.5%, 5% and 10%) as well as orally (at 100, 200 and 400 mg/kg p.o.) and their Psoriasis Area Severity Index (PASI) was calculated. The investigation also included determination of levels of TNF-α, IL-1β, IL-6 and IL-17 in the animal tissues, and the study scientifically justified the action against psoriasis of the ESX **[36]**.

Sushil K. Singh *et al*., (2015) Assessment of in vitro anti-psoriatic activity of selected Indian medicinal plants. Petroleum ether and ethanolic extracts of the selected plants like the whole plant, aerial parts etc were investigated for their in vitro anti-psoriatic activity and evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, using HaCaT cells. About 200 ml of varying concentrations of test samples were generated in cell culture medium and cultured for 24 hours before MTT testing to evaluate viable cells, and the results demonstrated that these plants had promising antiproliferative activity in skin keratinocytes. The extracts' inhibitory action on NO generation and lipid peroxidation in HaCaT cells demonstrated that their anti-psoriatic activity was mediated by an antioxidant mechanism, confirming the claims that these botanicals can be used to treat psoriasis **[37]**. Nguyen Thanh Tram *et al*., (2015) studied on the Assessment of anti-psoriatic activity of *Cassia fistula L*. extract incorporated cream by formulating the formulations containing fruit extract and were distinguished and accommodated for in vivo animal study. The methanol extract of the fruit was varied at different concentrations of 2.5, 3.75, 5.0, 6.25, and 0% (w/w) entrapped in oil-in-water topical emulsion to produce different formulations. Psoriasis-inflicted mice were tailored to suit for time-tested topical regimens with

prepared formulae, and dithranol 0.5 percent was used as a standard anti-psoriatic treatment. Histometric analysis of outcome measures such as degree of orthokeratosis and relative epidermal thickness revealed that most of the formulations containing methanol extract of *Cassia fistula* caused significant (P.001) Treatment with this herbal cream caused significant (P.001) degree of orthokeratosis when compared to untreated, whereas the medication with formula incorporating 6.25 percent extract had the attaining competitive advantage (40.811.19 percent) and caused significant (P.001) degree of orthokeratosis when compared to control **[38]**.

Vijayalakshmi A, *et al*., (2014) performed the Anti-psoriatic activity of *Givotia rottleriformis* in rats i.e., using (UV-B)-induced photodermatitis model in rats. The study involves four groups of animals(6/group) of which the control group received normal saline(10 ml/kg, po) and standard group with retinoic acid(0.5 mg/kg, po). Remaining groups were treated with ethanolic extract of bark of *Givotia rottleriformis* (200 and 400mg/kg, po) and analysed the data using one-way analysis of variance (ANOVA). The ethanolic extract exhibited significant reduction in percent of relative thickness of the epidermis and the crude extract ethanolic extract of *Givotia rottleriformis* bark seemed to have potent anti-psoriatic activity, thus according histopathological studies, and the ethanolic extract exhibited Munro's micro abscess is absent, rete ridges are lengthened, and capillary loops are inflated **[39]**. Ahmed JH, *et al*., (2014) performed a study on Evaluation of efficacy, safety and antioxidant effect of *Nigella sativa* in patients with psoriasis: A randomized clinical trial. Various drugs are used for treatment of psoriasis such as hydroxyurea, retinoids, methotrexate etc but are associated with many side effects and so this study evaluates the efficacy, safety of topical and oral doses of NS in psoriatic patients in which sixty patients with lenient to modest plaque and palmoplantar psoriasis randomly dividing into three groups; 20 patients in each. The ointment achieved 65% of good response, capsule produced 50% whereas the combination produced 85% of anti-psoriatic effect as it possess good anti-oxidant property **[40]**.

Ahmed JH, *et al*., (2014) described the study on The effectiveness of *Nigella sativa*, Methotrexate and their combination in the treatment of moderate to severe psoriasis. Methotrexate (MTX) is a commonly prescribed drug for patients with psoriasis.

Nigella sativa (NS) has been shown beneficial in vitiligo and in eczema. Sixty patients with moderate to severe plaque, palmoplantar and guttate psoriasis were enrolled for 12 weeks study divided into 3 groups; 20 patients in each. Marked response was attained in 60%,80%, 90% of patients on MTX,NS and (NS + MTX) respectively by decreasing oxidative stress. NS was well tolerated and showed ability in ameliorating gastric upset of MTX and the NS augmented anti-psoriatic effect of MTX. In mild cognitive psoriasis, topical and oral use of NS is valid and effective **[41]**.

Vijayalakshmi. A *et al*., (2014) evaluated the Anti-psoriatic activity of flavonoids from *Cassia tora* leaves using the rat ultraviolet B ray photodermatitis model of 3 different flavonoids, namely luteolin-7-O-E-glucopyranoside (1),formononetin-7-O-E-D-glucoside (2) and quercetin-3-O-E-D-glucuronide (3),extracted from the ethanol extract of *C. tora* leaves. They were also detected using HPLC by comparing the retention time of luteolin, quercetin, and formononetin, which are validated standards. In the UV triggered photodermatitis model, histological analysis of the section revealed the absence of Munro's micro abscess, elongation of rete ridges, and capillary loop dilation in the ethanol extract (400 mg/kg), isolated compound 2, 3, and standard groups. The ethanolic extract (400 mg/kg) and isolated phytochemicals 1, 2, and 3 showed a significant (p 0.01) percentage reduction in relative epidermal thickness when compared to the positive control, implying subtle anti-psoriatic activity **[42]**.

Dhanabal SP *et al*., (2012) performed the Screening of *Wrightia tinctoria* leaves for anti- psoriatic activity by using the mouse tail test. The screening was performed using a dose ranging from 200 mg/kg body weight in mice by using Isoretinoic acid (0.5 mg/kg) as the standard. The extract was also trialled for its antioxidant potential using DPPH, nitric oxide, and hydrogen peroxide radical scavenging assays, which led to substantial (p0.01) degree of orthokeratosis when compared to the control, and the drug activity was found to be 70.18 percent, which is more potent than the standard (57.43 percent), as well as an eminent anti-diabetic activity **[43]**.

Vijayalakshmi A, *et al*., (2012) performed the Screening of flavonoid " Quercetin" from the rhizome of *Smilax china Linn*. for anti-psoriatic activity using the mouse tail test. The parameters were changes in epidermal density and a proportion of orthokeratotic values. The anti-inflammatory role of the methanol extract and isolated flavonoid quercetin were evaluated using carrageenan-

induced pleurisy in rats which showed significant orthokeratosis and the in vitro anti-proliferent assay on HaCaT cell lines was also carried out. The methanol extract (200 mg/kg) and isolated flavonoid quercetin (50 mg/kg) showed anti-inflammatory effect in terms of significant inhibition ($P < 0.001$) in leukocyte migration which described its further use as an anti-psoriatic agent **[44]**.

Dwarampudi LP, *et al*., (2012) performed research on Anti-psoriatic activity and cytotoxicity of ethanolic extract of *Nigella sativa* seeds which are popularly known as black cumin with wide spectrum of pharmacological actions including anti-inflammatory, anti-bacterial, anti-fungal and anti-helminthic. This screened for anti-psoriatic activity of 95% ethanolic extract of *Nigella sativa* seeds using mouse tail model for psoriasis and invitro anti-psoriatic activity was carried out by SRB assay using HaCaT human keratinocyte cell lines which produced a significant epidermal differentiation from its gradation of orthokeratosis and the extract shown good anti-proliferative activity by a raise in epidermal thickness, confirming its use in traditional psoriasis treatment **[45]**.

Manmohan Singhal *et al*., (2012) aimed to prove *Cassia tora* L. Creams Inhibit Psoriasis in Mouse Tail Model. The plant *C. tora* has been traditionally used in treatment of number of skin diseases. As there is no established scientific proof for its anti-psoriatic activity, *Cassia tora* leaves methanol extract was prepared as various concentrations of O/W creams and trialled for acute dermal toxicity, The creams cleared the sensitivity, irritation, grittiness, and bleeding tests, implying that they could be safe up to a dose of 2,000 mg/kg. In the Mouse tail model, histological analysis of sections from the Test 2 (0.1 percent) and standard groups disclosed the paucity of Munro micro abscess, elongation of rete ridges, and capillary loop dilation. O/W creams and methanol extract of the leaves demonstrated a significant decrease in percent relative epidermal thickness and spleen index when compared to the positive control, indicating powerful anti-psoriatic efficacy **[46]**.

Chanachai Saelee *et al*., (2011) studied the Effects of Thai medicinal herb extracts with anti-psoriatic activity on the expression on NF-κB signaling biomarkers in HaCaT keratinocytes using a HaCaT keratinocyte cell line as an in vitro model. Previous, research showed that ethanolic extracts from three different Thai medicinal herbs, *Alpinia galanga, Curcuma longa and Annona squamosa,* had anti-psoriatic activity. This

study used semi-quantitative RT-PCR to see if the extracts played a key role in reducing psoriasis via regulation of NF-B signalling biomarkers, and found 10 different genes of the NF-B signalling network in HaC The extract produced from *Alpinia galanga* substantially improved TNFAIP3 expression while drastically reducing CSF-1 and NF-B2, corroborating the idea. CSF-1, IL-8, NF-B2, NF-B1, and RelA expression were dramatically reduced by *Curcuma longa* extract, but CD40 and NF-B1 expression were significantly reduced by *Annona squamosa* extract. As a result, the in vitro study suggested that these herbal extracts are capable of acting against psoriasis by controlling the expression of NF-B capable of detecting biomarkers, and thus also suggested that these herbal extracts are capable of acting against psoriasis by transcriptional activation of NF-B sensing biomarkers, and thus the in vitro survey found that these herbal extracts are capable of performing tasks against psoriasis by controlling the expression of CD40 and NF-B1 **[47]**. Leslie van der Fits *et al*., (2009) worked on the Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis IMQ was applied to the back skin of mice on a regular schedule, culminating in inflammatory scaly skin lesions that mirrored plaque type psoriasis, with increase in prevalence proliferation, abnormal differentiation, epidermal neutrophil accumulation in neoangiogenesis, misprocesses, and infiltrates of CD4 T cells, CD11c dendritic cells, and plasmacytoid dendritic cells. In mice lacking IL-17 or the IL-23 receptor, IMQ prompted epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increment in splenic Th17 cells, and the stimulated eczema was slightly dependent on the presence of T cells, whereas ailment advancement was almost completely blocked in mice lacking IL-17 or the IL-23 receptor implying that the IL-23/IL-17 axis plays a major role concluding the innate TLR7/8 ligand IMQ unilaterally causes a dermatitis that accurately reflects human psoriasis and is highly reliant on the IL-23/IL-17 axis **[48]**.

Shrivastav S. *et al*., (2009) studied on the Anti-psoriatic and phytochemical evaluation of *Thespesia populnea* bark extracts which were claimed to be useful in the therapy of scabies, psoriasis, ringworm, guineaworm, eczema and herpetic diseases. Three compounds TpF-1, TpF-2 & TpS-2 were isolated from thebark powder and an attempt was made to characterize them by physical, chemical and spectral data. The screening process was done by topical application of

different extracts & isolated compounds (TpF-1, TpF-2 & TpS-2). Finally successive pet-ether extract showed maximum anti-psoriatic activity (increased orthokeratotic region by 25%)amongst the extracts tested where as the compound TpF2 exhibited 38% increase in the same proving its anti-psoriatic activity **[49]**. Sonoko Masuda *et al*., (1993) studied the In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models (HPKlA and HPKlA-rus). Calcipotriol had first been converted into the 24-ketone (MC1046) and its 22,23-hydrogenated derivative (MC1080), both of which were found in bone cancer, kidney, and overexpressing cell lines, as well as the formation of extra added metabolites such as the two 23-hydroxylated derivatives of MC1080 (MC1439 and MC1441), the two 23,24-dihydroxylated compounds (MC1575 and 1577), and the side chain. These findings suggested that calcipotriol and calcitriol may share catabolic enzymes and biological activity of every massive metabolites of calcipotriol, as ascertained by a growth hormone reporter gene transactivation system (a vitamin D receptor assay), which was identified to be significantly smaller than that of calcipotriol **[50]**.

DISCUSSION

The remainder of activated T cells and related IL-17 outflow were reduced, diminishing psoriatic inflammation, and the gel also divulged a glucocorticoid-like response that could minimize recurrence of psoriasis **[1]**. When compared to the control, the data was analysed using one-way ANOVA followed by two-way ANOVA, which revealed a dramatic drop in epidermal thickness **[19]**. Among the extracts examined, the pet-ether extract showed the most anti-psoriatic action, while the compound TpF2 showed a 38 percent rise in the same, exemplifying its antipsoriatic activity **[49]**. These active ingredients are capable of acting against psoriasis by modulating the expression of NF-B capable of detecting biomarkers, and thus the in vitro results suggest that these herbal extracts are capable of acting against psoriasis by signaling pathways activation of NF-B sensing biomarkers, and thus the in vitro results suggest that these herbal extracts are capable of acting against psoriasis by transcriptional activation of NF-B data acquisition biomarker **[47]**.

CONCLUSION

Young researchers will benefit from the above-mentioned literature for further exploration. Additional research can be carried based on the data base access.

ACKNOWLEDGEMENT

This work would not have been possible without the services provided by Chalapathi institute of pharmaceutical sciences (Autonomous) and so I'm extremely grateful to the institution.

CONFLICTS OF INTEREST: Authors declare no conflict of interest.

REFERENCES:

[1] Liu, Liu, *et al*. "Celastrol Gel Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice by Targeting Langerhans Cells." *Biomedecine & Pharmacotherapie [Biomedicine & Pharmacotherapy]*, vol. 147, no. 112644, 2022, p. 112644, doi:10.1016/j.biopha.2022.112644.

[2] Morell, María, *et al*. "SIDT1 Plays a Key Role in Type I IFN Responses to Nucleic Acids in Plasmacytoid Dendritic Cells and Mediates the Pathogenesis of an Imiquimod-Induced Psoriasis Model." *EBioMedicine*, vol. 76, no. 103808, 2022, p. 103808, doi:10.1016/j.ebiom.2021.103808.

[3] Stuart, Philip E., *et al*. "Transethnic Analysis of Psoriasis Susceptibility in South Asians and Europeans Enhances Fine-Mapping in the MHC and Genomewide." *HGG Advances*, vol. 3, no. 1, 2022, p. 100069, doi:10.1016/j.xhgg.2021.100069.

[4] Mahtani, Renu, and Pradeep M. K. Nair. "Daily Oral Vitamin D3 without Concomitant Therapy in the Management of Psoriasis: A Case Series." *Clinical Immunology Communications*, vol. 2, 2022, pp. 17–22, doi:10.1016/j.clicom.2022.01.001.

[5] Wu, King-Jean, *et al*. "Severity of Periodontitis and Salivary Interleukin-1β Are Associated with Psoriasis Involvement." *Taiwan Yi Zhi [Journal of the Formosan Medical Association]*, 2022, doi:10.1016/j.jfma.2022.01.017.a

[6] Kemeriz, Funda, *et al*. "Evaluation of Ocular Psoriasis with Meibography." *Anais Brasileiros de Dermatologia*, vol. 97, no. 1, 2022, pp. 22–27, doi:10.1016/j.abd.2021.05.008.

[7] Shin, JooEun, *et al*. "IOX1 Impedes Host Inflammation in Imiquimod-Triggered Psoriasis." *Heliyon*, vol. 7, no. 11, 2021, p. e08433, doi:10.1016/j.heliyon.2021.e08433.

[8] Wadher, Kamlesh, *et al*. "Evaluation of Antipsoriatic Activity of Gel Containing *Pongamia Pinnata* Extract on Imiquimod-Induced Psoriasis." *Clinical Phytoscience*, vol. 7, no. 1, 2021, doi:10.1186/s40816-021-00256-6.

[9] Di, Tingting, *et al*. "Tuhuaiyin Alleviates Imiquimod-Induced Psoriasis via Inhibiting the Properties of IL-17-Producing Cells and Remodels the Gut Microbiota." *Biomedecine&Pharmacoth*

erapie [Biomedicine & Pharmacotherapy], vol. 141, no. 111884, 2021, p. 111884, doi:10.1016/j.biopha.2021.111884.

[10] Liu, Jared, *et al*. "Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T Cell Subsets during Treatment with Secukinumab." *JID Innovations*, no. 100094, 2021, p. 100094, doi:10.1016/j.xjidi.2021.100094.

[11] Hu, Yibo, *et al*. "Establishment and Validation of Psoriasis Evaluation Models." *Fundamental Research*, vol. 2, no. 1, 2022, pp. 166–176, doi:10.1016/j.fmre.2021.08.020.

[12] Qiu, Fen, *et al*. "Celastrol Niosome Hydrogel Has Anti-Inflammatory Effect on Skin Keratinocytes and Circulation without Systemic Drug Exposure in Psoriasis Mice." *International Journal of Nanomedicine*, vol. 16, 2021, pp. 6171–6182, doi:10.2147/IJN.S323208.

[13] Ibezim, Akachukwu, *et al*. "A Computational Multi-Targeting Approach for Drug Repositioning for Psoriasis Treatment." *BMC Complementary Medicine and Therapies*, vol. 21, no. 1, 2021, p. 193, doi:10.1186/s12906-021-03359-2.

[14] Loft, Nikolai, *et al*. "Disease Burden, Symptoms, and Use of Analgesics in Patients with Psoriasis with or without Psoriatic Arthritis: A Cross-Sectional Study." *Journal of the American Academy of Dermatology*, 2021, doi:10.1016/j.jaad.2021.07.028.

[15] Beytout, Q., *et al*. "Impact of the COVID-19 Pandemic on Children with Psoriasis." *Annales de Dermatologie et de Venereologie*, vol. 148, no. 2, 2021, pp. 106–111, doi:10.1016/j.annder.2021.01.005.

[16] Duarte, Gleison Vieira, *et al*. "Generalized Pustular Psoriasis in Brazil: A Public Claims Database Study." *JAAD International*, vol. 6, 2022, pp. 61–67, doi:10.1016/j.jdin.2021.12.001.

[17] Diakomopoulos, Achilleas, *et al*. "Understanding the Enigmatic Association between Mycosis Fungoides and Psoriasis: Report of Two Cases and Review of the Literature." *Metabolism Open*, vol. 12, no. 100148, 2021, p. 100148, doi:10.1016/j.metop.2021.100148.

[18] Perna, Danielle, *et al*. "Acute Generalized Pustular Psoriasis Exacerbated by the COVID-19 Vaccine." *JAAD Case Reports*, vol. 17, 2021, pp. 1–3, doi:10.1016/j.jdcr.2021.08.035.

[19] Lakshmi, Jada Naga, *et al*. "Evaluation of Anti-Psoriatic Activity of Selected Phytochemicals on UV-Induced Psoriasis in Mouse Tail Model." *Indian*

Journal of Physiology and Pharmacology, vol. 64, no. 123, 2020, pp. 123–128, doi:10.25259/ijpp_102_2020.

[20] Li, Hsin-Ju, *et al*. "Chrysin Alleviates Imiquimod-Induced Psoriasis-like Skin Inflammation and Reduces the Release of CCL20 and Antimicrobial Peptides." *Scientific Reports*, vol. 10, no. 1, 2020, p. 2932, doi:10.1038/s41598-020-60050-1.

[21] Wang, Shoufan, *et al*. "Salvianolic Acid B Ameliorates Psoriatic Changes in Imiquimod-Induced Psoriasis on BALB/c Mice by Inhibiting Inflammatory and Keratin Markers via Altering Phosphatidylinositol-3-Kinase/Protein Kinase B Signaling Pathway." *The Korean Journal of Physiology & Pharmacology: Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology*, vol. 24, no. 3, 2020, pp. 213–221, doi:10.4196/kjpp.2020.24.3.213.

[22] Khaledi, Mostafa, *et al*. "Chemical Profiling and Anti-Psoriatic Activity of Marine Sponge (*DysideaAvara*) in Induced Imiquimod-Psoriasis-Skin Model." *PloS One*, vol. 15, no. 11, 2020, p. e0241582, doi:10.1371/journal.pone.0241582.

[23] Asogwa, Fredrick C., *et al*. "Anti-Psoriatic and Immunomodulatory Evaluation of *PsorospermumFebrifugumSpach* and Its Phytochemicals." *Scientific African*, vol. 7, no. e00229, 2020, p. e00229, doi:10.1016/j.sciaf.2019.e00229.

[24] Ampawong, Sumate, *et al*. "Evaluating the Effect of Rice (*Oryza Sativa L.:* SRNC05053-6-2) Crude Extract on Psoriasis Using in Vitro and in Vivo Models." *Scientific Reports*, vol. 10, no. 1, 2020, p. 17618, doi:10.1038/s41598-020-74634-4.

[25] Halim, Sobia Ahsan, *et al*. "Diterpenoids and Triterpenoids from Frankincense Are Excellent Anti-Psoriatic Agents: An in Silico Approach." *Frontiers in Chemistry*, vol. 8, 2020, p. 486, doi:10.3389/fchem.2020.00486.

[26] Divya, Bharathi, *et al*. "Assessment of Anti-Psoriatic Activity of Ethanolic Extract of *Justicia Tranquebariensis Linn*. on Amelioration of IMQ-Induced Hyperkeratosis in Balb/C Mice." *Journal of Applied Pharmaceutical Science*, 2020, doi:10.7324/japs.2020.101211.

[27] Anitha, R. *Anti-Psoriatic Activity of Indigofera Tinctoria Leaves Extract on Staphylococcus aureus Embedded Hacat Cells: A Systematic Approach*, vol. 22, no. 11, 2020.

[28] Jacob, Janani, *et al*. "Evaluation of Anti-Psoriatic Potential of the Fruit

Rind of *Punica Granatum L*." *Pharmacognosy Journal*, vol. 11, no. 3, 2019, pp. 466–468, doi:10.5530/pj.2019.11.73.

[29] Negi, Poonam, *et al*. "Thymoquinone-Loaded Lipid Vesicles: A Promising Nanomedicine for Psoriasis." *BMC Complementary and Alternative Medicine*, vol. 19, no. 1, 2019, doi:10.1186/s12906-019-2675-5.

[30] Husna S, Ayesha, and Jayasankar Reddy. "Evaluation of Antipsoriatic Activity of Aqueous Extract of *Brassica Oleracea Var. Capitata* and Ethanolic Extract of *Mentha Spicata* Leaves on Imiquimod-Induced Psoriasis-like Dermatitis." *Asian Journal of Pharmaceutical and Clinical Research*, 2019, pp. 359–365, doi:10.22159/ajpcr.2019.v12i3.30693.

[31] Ravi, Anitha, *et al*. "Antioxidant Activity and In Silico Analysis of *Centella Asiatica* and *Indigofera Aspalathoides* in Psoriasis." *Biomedical and Pharmacology Journal*, vol. 11, no. 3, 2018, pp. 1403–1412, http://biomedpharmajournal.org/?p=21683.

[32] Kawahara, Takeshi, *et al*. "Effect of the Topical Application of an Ethanol Extract of Quince Seeds on the Development of Atopic Dermatitis-like Symptoms in NC/Nga Mice." *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, 2017, p. 80, doi:10.1186/s12906-017-1606-6.

[33] Liu, Han-Qing, *et al*. "Anti-Psoriasis Effects and Mechanisms of A-(8-Quinolinoxy) Zinc Phthalocyanine-Mediated Photodynamic Therapy." *Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology*, vol. 44, no. 1, 2017, pp. 200–214, doi:10.1159/000484647.

[34] Alex, Thomson, *et al*. "Evaluation of Anti Psoriatic Activity of *Karanjin* Oil." *Journal of Drug Delivery and Therapeutics*, vol. 7, no. 7, 2017, pp. 206–207, doi:10.22270/jddt.v7i7.1638.

[35] Banala, Rajkiran Reddy, *et al*. "Aqueous Extract of *Acalypha Indica* Leaves for the Treatment of Psoriasis: In-Vitro Studies." *International Journal of Bioassays*, vol. 6, no. 04, 2017, p. 5360, doi:10.21746/ijbio.2017.04.007.

[36] Parmar, Komal M., *et al*. "Anti-Psoriatic Potential of *Solanum Xanthocarpum* Stem in Imiquimod-Induced Psoriatic Mice Model." *Journal of Ethnopharmacology*, vol. 198, 2017, pp. 158–166, doi:10.1016/j.jep.2016.12.046.

[37] Singh, Sushil K., *et al*. "Assessment Of in Vitroantipsoriatic Activity of Selected Indian Medicinal

Plants." *Pharmaceutical Biology*, vol. 53, no. 9, 2015, pp. 1295–1301, doi:10.3109/13880209.2014.976713.

[38] Tram, Nguyen, and Hoang Son. "Assessment of Anti-Psoriatic Activity of *Cassia Fistula L.* Extract Incorporated Cream." *British Journal of Pharmaceutical Research*, vol. 5, no. 6, 2015, pp. 370–378, doi:10.9734/bjpr/2015/15997.

[39] Vijayalakshmi, A., and Madhira Geetha. "Anti-Psoriatic Activity of *GivotiaRottleriformis* in Rats." *Indian Journal of Pharmacology*, vol. 46, no. 4, 2014, pp. 386–390, doi:10.4103/0253-7613.135949.

[40] Ahmed, Jawad Hassan, *et al*. "Evaluation of Efficacy, Safety and Antioxidant Effect of *Nigella Sativa* in Patients with Psoriasis: A Randomized Clinical Trial." *Journal of Clinical and Experimental Investigations*, vol. 5, no. 2, 2014, pp. 186–193, doi:10.5799/ahinjs.01.2014.02.0387.

[41] Ahmed, Jawad Hassan, Sheima Nadim Kadhim, *et al*. "The Effectiveness of *Nigella Sativa*, Methotrexate and Their Combination in the Treatment of Moderate to Severe Psoriasis." *Journal of Clinical and Experimental Investigations*, vol. 5, no. 4, 2014, pp. 521–528, doi:10.5799/ahinjs.01.2014.04.0450.

[42] Vijayalakshmi, A., and Geetha Madhira. "Anti-Psoriatic Activity of Flavonoids from *Cassia tora* Leaves Using the Rat Ultraviolet B Ray Photodermatitis Model." *RevistaBrasileira de Farmacognosia: OrgaoOficial Da SociedadeBrasileira de Farmacognosia*, vol. 24, no. 3, 2014, pp. 322–329, doi:10.1016/j.bjp.2014.07.010.

[43] Dhanabal SP*, Baskar Anand Raj, Muruganantham N, Praveen TK, Raghu PS "Screening of *Wrightia tinctoria* leaves for Anti psoriatic activity." Hygeia Journal for drugs and medicines, vol. 4, no. 1, 2012, pp. 73-78.

[44] Vijayalakshmi, A., *et al*. "Screening of Flavonoid 'Quercetin' from the Rhizome of *Smilax China Linn*. for Anti-Psoriatic Activity." *Asian Pacific Journal of Tropical Biomedicine*, vol. 2, no. 4, 2012, pp. 269–275, doi:10.1016/S2221-1691(12)60021-5.

[45] Dwarampudi, Lalitha Priyanka, *et al*. "Antipsoriatic Activity and Cytotoxicity of Ethanolic Extract of *Nigella Sativa* Seeds." *Pharmacognosy Magazine*, vol. 8, no. 32, 2012, pp. 268–272, doi:10.4103/0973-1296.103650.

[46] Singhal, Manmohan. "*Cassia Tora L.* Creams Inhibit Psoriasis in Mouse Tail

Model." *Pharmaceutical Crops*, vol. 3, no. 1, 2012, pp. 1–6, doi:10.2174/2210290601203010001.

[47] Saelee, Chanachai, *et al*. "Effects of Thai Medicinal Herb Extracts with Anti-Psoriatic Activity on the Expression on NF-KB Signaling Biomarkers in HaCaT Keratinocytes." *Molecules (Basel, Switzerland)*, vol. 16, no. 5, 2011, pp. 3908–3932, doi:10.3390/molecules16053908.

[48] Nadeem, Ahmed, *et al*. "Imiquimod-Induced Psoriasis-like Skin Inflammation Is Suppressed by BET Bromodomain Inhibitor in Mice through RORC/IL-17A PathwayModulation." *Pharmacological Research: The Official Journal of the Italian Pharmacological Society*, vol. 99, 2015, pp. 248–257, doi:10.1016/j.phrs.2015.06.001.

[49] Shrivastav, S. *et al*. "Anti-psoriatic and phytochemical evaluation of *Thespesia populnea* bark extracts." (2009).

[50] Masuda, S., *et al*. "In Vitro Metabolism of the Anti-Psoriatic Vitamin D Analog, Calcipotriol, in Two Cultured Human Keratinocyte Models." *The Journal of Biological Chemistry*, vol. 269, no. 7, 1994, pp. 4794–4803, doi:10.1016/s0021-9258(17)37614-7.